Harris Kupperman thinks it's worth in the mid teens.That kind of makes sense when the p/e of this stock is around 2x next year and possibly 1x the year afterwards.
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game